MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.6221
-0.0034
-0.54%
Opening 09:34 03/18 EDT
OPEN
0.6300
PREV CLOSE
0.6255
HIGH
0.6300
LOW
0.6221
VOLUME
6.47K
TURNOVER
--
52 WEEK HIGH
1.530
52 WEEK LOW
0.5803
MARKET CAP
53.76M
P/E (TTM)
-2.1533
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONCY last week (0310-0314)?
Weekly Report · 1d ago
Oncolytics Biotech: Continuing To Justify The Negativity
Seeking Alpha · 03/11 03:36
Oncolytics Biotech Price Target Cut to $3.00/Share From $5.00 by Maxim Group
Dow Jones · 03/10 18:43
Oncolytics Biotech Is Maintained at Buy by Maxim Group
Dow Jones · 03/10 18:43
Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03/10 17:40
Oncolytics Biotech Is Maintained at Outperform by RBC Capital
Dow Jones · 03/10 16:53
Oncolytics Biotech Price Target Cut to $5.00/Share From $6.00 by RBC Capital
Dow Jones · 03/10 16:53
RBC Capital Maintains Outperform on Oncolytics Biotech, Lowers Price Target to $5
Benzinga · 03/10 16:42
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc (USA) stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.